论文部分内容阅读
目的观察人乳癌新辅助化疗前后MCM5、Ki-67和C-erbB-2蛋白的表达情况,探讨其与化疗效果的关系。方法采用免疫组化法检测新辅助化疗前后40例乳癌标本中MCM5、Ki-67和C-erbB-2的表达。结果新辅助化疗有效率为77.5%。化疗前MCM5和Ki-67蛋白阳性表达显著高于化疗后(Z=-3.94、-3.04,P<0.01),而化疗前后C-erbB-2蛋白阳性表达差异无显著性(Z=-1.60,P>0.05);化疗前MCM5蛋白阳性表达显著高于Ki-67(Z=-4.02,P<0.01)。化疗有效组(31例)MCM5蛋白阳性表达显著高于化疗无效组(9例)(Z=-3.57,P<0.01),而C-erbB-2蛋白阳性表达显著低于化疗无效组(Z=-3.92,P<0.01)。结论ET方案新辅助化疗有较好的疗效,可能通过抑制MCM5、Ki-67蛋白的表达来阻止乳癌细胞的增殖。MCM5高表达、C-erbB-2阴性者化疗更为敏感,二者可作为临床指导乳癌化疗的分子生物学指标。
Objective To observe the expression of MCM5, Ki-67 and C-erbB-2 protein in human breast cancer before and after neoadjuvant chemotherapy, and to explore their relationship with the effect of chemotherapy. Methods Immunohistochemistry was used to detect the expression of MCM5, Ki-67 and C-erbB-2 in 40 breast cancer samples before and after neoadjuvant chemotherapy. Results The neoadjuvant chemotherapy rate was 77.5%. The positive expression rates of MCM5 and Ki-67 before chemotherapy were significantly higher than those after chemotherapy (Z = -3.94, -3.04, P <0.01), but there was no significant difference in the expression of C-erbB-2 before and after chemotherapy P> 0.05). The positive expression of MCM5 protein before chemotherapy was significantly higher than that of Ki-67 (Z = -4.02, P <0.01). The positive expression rate of MCM5 in chemotherapy-effective group (31 cases) was significantly higher than that in chemotherapy-ineffective group (Z = -3.57, P <0.01), while the expression of C-erbB- -3.92, P <0.01). Conclusion ET neoadjuvant chemotherapy has a good curative effect, may inhibit the proliferation of breast cancer cells by inhibiting the expression of MCM5, Ki-67 protein. MCM5 overexpression, C-erbB-2-negative chemotherapy is more sensitive, the two can be used as a clinical indicator of breast cancer chemotherapy molecular biology.